Chitosan Derivative-Based Microspheres Loaded with Fibroblast Growth Factor for the Treatment of Diabetes

Overview

Journal Polymers (Basel)

Publisher MDPI

Date 2023 Jul 29

PMID 37514488

Authors

Jue Wu

Qian Chen

Wenfei Wang

Yuhong Lin

Hong Kang

Zheng Jin

Kai Zhao

Affiliations

Soon will be listed here.

Abstract

Diabetes mellitus type 2 (T2DM) is a disease caused by genetic and environmental factors, and the main clinical manifestation is hyperglycemia. Currently, insulin injections are still the first-line treatment for diabetes. However, repeated injections may cause insulin resistance, hypoglycemia, and other serious side effects. Thus, it is imperative to develop new diabetes treatments. Protein-based diabetes drugs, such as fibroblast growth factor-21 (FGF-21), have a longer-lasting glycemic modulating effect with high biosafety. However, the instability of these protein drugs limits their applications. In this study, we extract protein hypoglycemic drugs with oral and injectable functions. The FGF-21 analog (NA-FGF) was loaded into the chitosan derivative-based nanomaterials, N-2-Hydroxypropyl trimethyl ammonium chloride chitosan/carboxymethyl chitosan (N-2-HACC/CMCS), to prepare NA-FGF-loaded N-2-HACC/CMCS microspheres (NA-FGF-N-2-HACC/CMCS MPs). It was well demonstrated that NA-FGF-N-2-HACC/CMCS MPs have great biocompatibility, biostability, and durable drug-release ability. In addition to injectable drug delivery, our prepared microspheres were highly advantageous for oral administration. The in vitro and in vivo experimental results suggested that NA-FGF-N-2-HACC/CMCS MPs could be used as a promising candidate and universal nano-delivery system for both oral and injectable hypoglycemic regulation.

Citing Articles

Advances in Nanomedicine for Precision Insulin Delivery.

Caturano A, Nilo R, Nilo D, Russo V, Santonastaso E, Galiero R Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065795 PMC: 11279564. DOI: 10.3390/ph17070945.

References

Huang W, Wang Y, Huang Z, Wang X, Chen L, Zhang Y . On-Demand Dissolvable Self-Healing Hydrogel Based on Carboxymethyl Chitosan and Cellulose Nanocrystal for Deep Partial Thickness Burn Wound Healing. ACS Appl Mater Interfaces. 2018; 10(48):41076-41088. DOI: 10.1021/acsami.8b14526. View

Dua K, Bebawy M, Awasthi R, Tekade R, Tekade M, Gupta G . Application of Chitosan and its Derivatives in Nanocarrier Based Pulmonary Drug Delivery Systems. Pharm Nanotechnol. 2017; 5(4):243-249. DOI: 10.2174/2211738505666170808095258. View

Zhang P, Li S, Zhang S, Zhang X, Wan L, Yun Z . GRGDS-functionalized chitosan nanoparticles as a potential intravenous hemostat for traumatic hemorrhage control in an animal model. Nanomedicine. 2018; 14(8):2531-2540. DOI: 10.1016/j.nano.2018.08.007. View

Sun Y, Juan J, Xu Q, Su R, Hirst J, Yang H . Increasing insulin resistance predicts adverse pregnancy outcomes in women with gestational diabetes mellitus. J Diabetes. 2019; 12(6):438-446. DOI: 10.1111/1753-0407.13013. View

Szkudelski T, Konieczna K, Szkudelska K . Regulatory Effects of Metformin, an Antidiabetic Biguanide Drug, on the Metabolism of Primary Rat Adipocytes. Molecules. 2022; 27(16). PMC: 9415039. DOI: 10.3390/molecules27165250. View

Ihana-Sugiyama N, Sugiyama T, Tanaka H, Ueki K, Kobayashi Y, Ohsugi M . Comparison of effectiveness and drug cost between dipeptidyl peptidase-4 inhibitor and biguanide as the first-line anti-hyperglycaemic medication among Japanese working generation with type 2 diabetes. J Eval Clin Pract. 2019; 26(1):299-307. PMC: 7004211. DOI: 10.1111/jep.13171. View

Coppage A, Heard K, DiMare M, Liu Y, Wu W, Lai J . Human FGF-21 Is a Substrate of Fibroblast Activation Protein. PLoS One. 2016; 11(3):e0151269. PMC: 4786124. DOI: 10.1371/journal.pone.0151269. View

Richardson T, Kerr D . Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003; 4(10):661-7. DOI: 10.2165/00128071-200304100-00001. View

Wang W, Meng Q, Li Q, Liu J, Zhou M, Jin Z . Chitosan Derivatives and Their Application in Biomedicine. Int J Mol Sci. 2020; 21(2). PMC: 7014278. DOI: 10.3390/ijms21020487. View

10.

Nguyen M, Wyatt H, Susser L, Geoffrion M, Rasheed A, Duchez A . Delivery of MicroRNAs by Chitosan Nanoparticles to Functionally Alter Macrophage Cholesterol Efflux in Vitro and in Vivo. ACS Nano. 2019; 13(6):6491-6505. DOI: 10.1021/acsnano.8b09679. View

11.

Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Zhou H . Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial. BMC Med. 2013; 11:160. PMC: 3716981. DOI: 10.1186/1741-7015-11-160. View

12.

Yang Q, Sun J, Shao D, Zhang H, Bai C, Cao F . The Association between Diabetes Complications, Diabetes Distress, and Depressive Symptoms in Patients with Type 2 Diabetes Mellitus. Clin Nurs Res. 2020; 30(3):293-301. DOI: 10.1177/1054773820951933. View

13.

Ding Y, Li S, Liang L, Huang Q, Yuwen L, Yang W . Highly Biocompatible Chlorin e6-Loaded Chitosan Nanoparticles for Improved Photodynamic Cancer Therapy. ACS Appl Mater Interfaces. 2018; 10(12):9980-9987. DOI: 10.1021/acsami.8b01522. View

14.

Lisuzzo L, Cavallaro G, Milioto S, Lazzara G . Halloysite Nanotubes Coated by Chitosan for the Controlled Release of Khellin. Polymers (Basel). 2020; 12(8). PMC: 7464246. DOI: 10.3390/polym12081766. View

15.

Wei W, Ehlerding E, Lan X, Luo Q, Cai W . Molecular imaging of β-cells: diabetes and beyond. Adv Drug Deliv Rev. 2019; 139:16-31. PMC: 6686871. DOI: 10.1016/j.addr.2018.06.022. View

16.

Ding F, Fu J, Tao C, Yu Y, He X, Gao Y . Recent Advances of Chitosan and its Derivatives in Biomedical Applications. Curr Med Chem. 2019; 27(18):3023-3045. DOI: 10.2174/0929867326666190405151538. View

17.

Rigato M, Avogaro A, de Kreutzenberg S, Fadini G . Effects of Basal Insulin on Lipid Profile Compared to Other Classes of Antihyperglycemic Agents in Type 2 Diabetic Patients. J Clin Endocrinol Metab. 2020; 105(7). DOI: 10.1210/clinem/dgaa178. View

18.

Wang M, Wang C, Ren S, Pan J, Wang Y, Shen Y . Versatile Oral Insulin Delivery Nanosystems: From Materials to Nanostructures. Int J Mol Sci. 2022; 23(6). PMC: 8952690. DOI: 10.3390/ijms23063362. View

19.

Azmana M, Mahmood S, Hilles A, Rahman A, Arifin M, Ahmed S . A review on chitosan and chitosan-based bionanocomposites: Promising material for combatting global issues and its applications. Int J Biol Macromol. 2021; 185:832-848. DOI: 10.1016/j.ijbiomac.2021.07.023. View

20.

Lee S, Choi S, Lee H, Song M, Kim Y, Jeong J . A Class I Histone Deacetylase Inhibitor Attenuates Insulin Resistance and Inflammation in Palmitate-Treated C2C12 Myotubes and Muscle of HF/HFr Diet Mice. Front Pharmacol. 2020; 11:601448. PMC: 7758468. DOI: 10.3389/fphar.2020.601448. View